AR and prostate carcinoma: Furthermore, an additional study (NCT04989946), currently in the recruitment phase, aims to assess the utilization of ADT, either in conjunction with or without plasmid DNA vaccine encoding human androgen receptor (pTVG-AR), and with or without Nivolumab, for the treatment of patients who have been newly diagnosed with high-risk prostate cancer.